{"id":"W2988075996","doi":"10.1182/blood-2019-125963","title":"Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Cyclophosphamide; Oncology; Pembrolizumab; Refractory (planetary science); Gastroenterology; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002058065,0.001207228,0.001838859,0.0004270566,0.0002201382,0.0009540633,0.0009013205,0.0009145749,0.002844159],"category_scores_gemma":[0.0006625275,0.0004258895,0.001720743,0.0002982802,0.0006480162,0.0007979593,0.0004685286,0.002007355,0.000892827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005715439,"about_ca_system_score_gemma":0.0006852931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003857832,"about_ca_topic_score_gemma":0.0008745123,"domain_scores_codex":[0.9995432,0.0002384569,0.00002732223,0.00006376512,0.00007297597,0.00005437334],"domain_scores_gemma":[0.9996076,0.00006889688,0.00007769108,0.00004788304,0.00003590534,0.0001620106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.625783,0.0477556,0.01027294,0.003395729,0.009923821,0.0005383179,0.0004409696,0.003657589,0.04295463,0.0007476527,0.005496117,0.2490337],"study_design_scores_gemma":[0.3893465,0.5737498,0.01999675,0.000185624,0.003226099,0.000541798,0.0001683243,0.001373123,0.002967442,0.000317813,0.008056511,0.0000703054],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842147,0.01045705,0.0003684796,0.0006126144,0.0001664145,0.0006019343,0.0005330194,0.00009827822,0.002947616],"genre_scores_gemma":[0.988196,0.005160104,0.0008294022,0.001101125,0.0002079352,0.0006938535,0.001291058,0.00002238289,0.0024982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002844159,"threshold_uncertainty_score":0.01088417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0162301028643446,"score_gpt":0.2928902198724473,"score_spread":0.2766601170081027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}